))
Justin Chickles, CEO & Co-Founder of Glycyx Therapeutics
Manage episode 500369611 series 3399898
Content provided by Julio G. Martinez-Clark. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Julio G. Martinez-Clark or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Could opioids be silently undermining cancer immunotherapy?
This week, Justin Chickles — CEO and co-founder of Glycyx Therapeutics — explains how his team is tackling this overlooked challenge with axelopran, a breakthrough therapy now advancing to Phase 2 trials.
From his early career at Johnson & Johnson to leading multiple startups, Justin offers a rare, insider’s perspective on driving biotech innovation from concept to clinic. If you’re interested in cutting-edge oncology, translational science, and biotech entrepreneurship, you won’t want to miss this episode.
107 episodes
Share
